Remove Atherosclerosis Remove Circulation Remove Risk Factors
article thumbnail

Winning the Battle Against Atherosclerosis: Practical, Proactive Solutions

Cardiometabolic Health Congress

Atherosclerosis (ASVD) remains a leading driver of cardiovascular disease (CVD), a global health challenge that claims millions of lives each year. Explore actionable, evidence-based strategies to combat traditional and emerging risk factors, with a focus on precision approaches and primordial prevention.

article thumbnail

Why Waiting Until Age 50 To Address Risk Factors For Heart Disease Is Too Late.

Dr. Paddy Barrett

And plaque in your coronary arteries is the result of exposure to risk factors over time. These individuals then must have had one or more risk factors for a long time prior to their heart attack. The answer: Risk Factors. But wouldn’t such risk factors have been obvious?

article thumbnail

2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Circulation

Circulation, Ahead of Print.

article thumbnail

Beating the Odds: Inside the Tribe with a Near-Zero Rate of Heart Disease.

Dr. Paddy Barrett

Share While the average Western male and female will develop advanced coronary artery disease by age 55 and 66, respectively, 85% of the Tsimane tribe population over 40 had no evidence of advanced atherosclerosis 2. Coronary atherosclerosis, as evidenced by an abnormal CAC score, is a measure of advanced plaque. Circulation.

article thumbnail

Why Measuring ApoB Is The Key To Preventing Heart Disease.

Dr. Paddy Barrett

This Is Known As Atherosclerosis. The fundamental cause of atherosclerosis is when a cholesterol particle crosses into the artery wall from the bloodstream, gets stuck, and sets off an inflammatory process 1. ApoB particles crossing the artery wall to cause Atherosclerosis. No atherosclerosis. No heart attacks.

article thumbnail

Trial Results: Low-Dose Colchicine HelpsTreat Cardiovascular Disease

DAIC

mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. Specifically, LODOCO reduces cardiac event risk in adult patients with established atherosclerotic cardiovascular disease by an additional 31% as compared to placebo.

article thumbnail

Abstract TP300: Apolipoprotein-E Deficiency and High Fat Diet Alter Immunomodulatory Cellular and Molecular Determinants Promoting Atherosclerosis, a Stroke Risk Factor

Stroke Journal

Background:Most ischemic strokes are caused by atherosclerosis. Apolipoprotein E (ApoE) regulates lipid metabolism, and its deficiency is associated with dyslipidemia and atherosclerosis. Poor dietary habits promote the onset of atherosclerosis. Targeted proteomic profiling identified the circulating inflammatory proteins.